Treatment of Diabetes in People With Heart Failure

Canadian Journal of Diabetes

Volumn 42, Issue , 2018, Pages S196-S200

  Connelly, Kim A ^a   Gilbert, Richard E ^a   Liu, Peter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; ENALAPRIL; GLICLAZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INDAPAMIDE PLUS PERINDOPRIL; IVABRADINE; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; PIOGLITAZONE; PLACEBO; RAMIPRIL; ROSIGLITAZONE; SACUBITRIL PLUS VALSARTAN; SAXAGLIPTIN; SEMAGLUTIDE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; TROPONIN T; ANTIDIABETIC AGENT;

ADD ON THERAPY; ARTICLE; BLOOD ANALYSIS; COMORBIDITY; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; LACTIC ACIDOSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; RISK REDUCTION; THORAX RADIOGRAPHY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; COMPLICATION; DIABETES MELLITUS; PROGNOSIS; STANDARDS;

DIABETES MELLITUS; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS;

EID: 85044780543     PISSN: 14992671     EISSN: 23523840     Source Type: Journal    
DOI: 10.1016/j.jcjd.2017.10.026     Document Type: Article

References (58)

1. Krum, H., Gilbert, R.E., Demographics and concomitant disorders in heart failure. Lancet 362 (2003), 147–158.
2. Albertini, J.P., Cohen, R., Valensi, P., et al. B-type natriuretic peptide, a marker of asymptomatic left ventricular dysfunction in type 2 diabetic patients. Diabetes Metab 34 (2008), 355–362.
3. O'Donoghue, M., Kenney, P., Oestreicher, E., et al. Usefulness of aminoterminal pro-brain natriuretic peptide testing for the diagnostic and prognostic evaluation of dyspneic patients with diabetes mellitus seen in the emergency department (from the PRIDE Study). Am J Cardiol 100 (2007), 1336–1340.
4. Ohkuma, T., Jun, M., Woodward, M., et al. Cardiac stress and inflammatory markers as predictors of heart failure in patients with type 2 diabetes: The ADVANCE trial. Diabetes Care, 40, 2017 pii: cd170509.
5. Valle, R., Bagolin, E., Canali, C., et al. The BNP assay does not identify mild left ventricular diastolic dysfunction in asymptomatic diabetic patients. Eur J Echocardiogr 7 (2006), 40–44.
6. Shimabukuro, M., Higa, N., Oshiro, Y., et al. Diagnostic utility of brain-natriuretic peptide for left ventricular diastolic dysfunction in asymptomatic type 2 diabetic patients. Diabetes Obes Metab 9 (2007), 323–329.
7. Galderisi, M., Diastolic dysfunction and diabetic cardiomyopathy: Evaluation by Doppler echocardiography. J Am Coll Cardiol 48 (2006), 1548–1551.
8. Karavanaki, K., Kazianis, G., Konstantopoulos, I., et al. Early signs of left ventricular dysfunction in adolescents with type 1 diabetes mellitus: The importance of impaired circadian modulation of blood pressure and heart rate. J Endocrinol Invest 31 (2008), 289–296.
9. Grandi, A.M., Piantanida, E., Franzetti, I., et al. Effect of glycemic control on left ventricular diastolic function in type 1 diabetes mellitus. Am J Cardiol 97 (2006), 71–76.
10. Ng, A.C., Delgado, V., Bertini, M., et al. Findings from left ventricular strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol 104 (2009), 1398–1401.
11. Mishra, T.K., Rath, P.K., Mohanty, N.K., et al. Left ventricular systolic and diastolic dysfunction and their relationship with microvascular complications in normotensive, asymptomatic patients with type 2 diabetes mellitus. Indian Heart J 60 (2008), 548–553.
12. Ashraf, S.M.S., Basir, F., Association of hypertension and diastolic dysfunction with type-2 diabetes mellitus. Pakistan J Med Sci 23 (2007), 344–348.
13. Stahrenberg, R., Edelmann, F., Mende, M., et al. Association of glucose metabolism with diastolic function along the diabetic continuum. Diabetologia 53 (2010), 1331–1340.
14. Dinh, W., Futh, R., Lankisch, M., et al. Cardiovascular autonomic neuropathy contributes to left ventricular diastolic dysfunction in subjects with type 2 diabetes and impaired glucose tolerance undergoing coronary angiography. Diabet Med 28 (2011), 311–318.
15. From, A.M., Scott, C.G., Chen, H.H., Changes in diastolic dysfunction in diabetes mellitus over time. Am J Cardiol 103 (2009), 1463–1466.
16. Aguilar, D., Deswal, A., Ramasubbu, K., et al. Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. Am J Cardiol 105 (2010), 373–377.
17. Ghali, J.K., Boehmer, J., Feldman, A.M., et al. Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure. J Card Fail 13 (2007), 769–773.
18. Fantoni, C., Regoli, F., Ghanem, A., et al. Long-term outcome in diabetic heart failure patients treated with cardiac resynchronization therapy. Eur J Heart Fail 10 (2008), 298–307.
19. Haas, S.J., Vos, T., Gilbert, R.E., et al. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 146 (2003), 848–853.
20. McMurray, J.J., Packer, M., Desai, A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
21. Kristensen, S.L., Preiss, D., Jhund, P.S., et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: Insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail, 9, 2016 pii: e002560.
22. Komajda, M., Tavazzi, L., Francq, B.G., et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: An analysis from the SHIFT trial. Eur J Heart Fail 17 (2015), 1294–1301.
23. Ezekowitz, J.A., O'Meara, E., McDonald, M.A., et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Can J Cardiol 33 (2017), 1342–1433.
24. Lopes, R.J., Lourenco, A.P., Mascarenhas, J., et al. Safety of spironolactone use in ambulatory heart failure patients. Clin Cardiol 31 (2008), 509–513.
25. Desai, A.S., Swedberg, K., McMurray, J.J., et al. Incidence and predictors of hyperkalemia in patients with heart failure: An analysis of the CHARM Program. J Am Coll Cardiol 50 (2007), 1959–1966.
26. Sadjadi, S.A., McMillan, J.I., Jaipaul, N., et al. A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. Ther Clin Risk Manag 5 (2009), 547–552.
27. Phillips, C.O., Kashani, A., Ko, D.K., et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: A quantitative review of data from randomized clinical trials. Arch Intern Med 167 (2007), 1930–1936.
28. Raebel, M.A., McClure, D.L., Chan, K.A., et al. Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: Are we monitoring for hyperkalemia?. Ann Pharmacother 41 (2007), 193–200.
29. Raebel, M.A., Ross, C., Xu, S., et al. Diabetes and drug-associated hyperkalemia: Effect of potassium monitoring. J Gen Intern Med 25 (2010), 326–333.
30. Feuvray, D., Darmellah, A., Diabetes-related metabolic perturbations in cardiac myocyte. Diabetes Metab 34 (2008), S3–S9.
31. Wenmeng, W., Qizhu, T., Early administration of trimetazidine may prevent or ameliorate diabetic cardiomyopathy. Med Hypotheses 76 (2011), 181–183.
32. Belardinelli, R., Cianci, G., Gigli, M., et al. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy. J Cardiovasc Pharmacol 51 (2008), 611–615.
33. Bell, D.S., Lukas, M.A., Holdbrook, F.K., et al. The effect of carvedilol on mortality risk in heart failure patients with diabetes: Results of a meta-analysis. Curr Med Res Opin 22 (2006), 287–296.
34. Gilbert, R.E., Krum, H., Heart failure in diabetes: Effects of anti-hyperglycaemic drug therapy. Lancet 385 (2015), 2107–2117.
35. Salpeter, S.R., Greyber, E., Pasternak, G.A., et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev(4), 2010 CD002967.
36. Salpeter, S.R., Greyber, E., Pasternak, G.A., et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: Systematic review and meta-analysis. Arch Intern Med 163 (2003), 2594–2602.
37. Andersson, C., Olesen, J.B., Hansen, P.R., et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: A retrospective nationwide cohort study. Diabetologia 53 (2010), 2546–2553.
38. Eurich, D.T., Weir, D.L., Majumdar, S.R., et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: Systematic review of observational studies involving 34,000 patients. Circ Heart Fail 6 (2013), 395–402.
39. Pfister, R., Cairns, R., Erdmann, E., et al. A clinical risk score for heart failure in patients with type 2 diabetes and macrovascular disease: An analysis of the PROactive study. Int J Cardiol 162 (2013), 112–116.
40. Home, P.D., Pocock, S.J., Beck-Nielsen, H., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet 373 (2009), 2125–2135.
41. Lago, R.M., Singh, P.P., Nesto, R.W., Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: A meta-analysis of randomised clinical trials. Lancet 370 (2007), 1129–1136.
42. Yacoub, R., Habib, H., Lahdo, A., et al. Association between smoking and chronic kidney disease: A case control study. BMC Public Health, 10, 2010, 731.
43. Scirica, B.M., Bhatt, D.L., Braunwald, E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
44. Green, J.B., Bethel, M.A., Armstrong, P.W., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
45. White, W.B., Cannon, C.P., Heller, S.R., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 (2013), 1327–1335.
46. Scirica, B.M., Braunwald, E., Raz, I., et al. Heart failure, saxagliptin, and diabetes mellitus: Observations from the SAVOR-TIMI 53 randomized trial. Circulation 130 (2014), 1579–1588.
47. Yu, O.H., Filion, K.B., Azoulay, L., et al. Incretin-based drugs and the risk of congestive heart failure. Diabetes Care 38 (2015), 277–284.
48. Product monograph Pr ONGLYZA saxagliptin tablets, 2016, AstraZeneca Canada Inc, Mississauga https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/onglyza-product-monograph-en.pdf.
49. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
50. Pfeffer, M.A., Claggett, B., Diaz, R., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
51. Marso, S.P., Bain, S.C., Consoli, A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
52. Margulies, K.B., Hernandez, A.F., Redfield, M.M., et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: A randomized clinical trial. JAMA 316 (2016), 500–508.
53. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
54. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
55. Study to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction. AstraZeneca https://clinicaltrials.gov/ct2/show/NCT03036124, 2017.
56. A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic heart failure with reduced ejection fraction (HFrEF). Boehringer Ingelheim https://clinicaltrials.gov/ct2/show/NCT03057977, 2017.
57. A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF). Boehrigner Ingelheim https://clinicaltrials.gov/ct2/show/NCT03057951, 2017.
58. Moher, D., Liberati, A., Tetzlaff, J., et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med, 6, 2009 e1000097.